Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib and Pembrolizumab in Progressed NSCLC
NCT04670107Phase 2Completed
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Jun 2018
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib in non-small cell lung cancer (NSCLC), sponsored by The Affiliated Hospital of Qingdao University. Started Jun 2018; status: completed.
02
Drugs
anlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04670107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04670107.